SEC Comment Letter 0000000000-26-003470 to RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC.
Date: April 7, 2026 · CIK: 0001553643 · Accession: 0000000000-26-003470
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294885
Letter
Re: Relmada Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294885 Dear Sergio Traversa:
April 7, 2026
Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Steven M. Skolnick, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 7, 2026 Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 Re: Relmada Therapeutics, Inc. Registration Statement on Form S-3 Filed April 3, 2026 File No. 333-294885 Dear Sergio Traversa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven M. Skolnick, Esq. </TEXT> </DOCUMENT>